# EDGAR Filing Document

**Accession Number:** 0001267565
**File Stem:** 0001296771-26-000002
**Filing Date:** 2026-5
**Character Count:** 7662
**Document Hash:** d705f26799761850bda5b77364d6452e
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001296771-26-000002.hdr.sgml**: 20260518

**ACCESSION NUMBER**: 0001296771-26-000002

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260514

**FILED AS OF DATE**: 20260518

**DATE AS OF CHANGE**: 20260518

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Freund John Gordon
- **CENTRAL INDEX KEY:** 0001296771

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37372
- **FILM NUMBER:** 26993455

**MAIL ADDRESS:**
- **STREET 1:** 125 UNIVERSITY AVE.
- **STREET 2:** C/O SKYLINE VENTURES
- **CITY:** PALO ALTO
- **STATE:** CA
- **ZIP:** 94301
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** COLLEGIUM PHARMACEUTICAL, INC
- **CENTRAL INDEX KEY:** 0001267565
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** VA
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 100 TECHNOLOGY CENTER DRIVE
- **CITY:** STOUGHTON
- **STATE:** MA
- **ZIP:** 02072
- **BUSINESS PHONE:** 781-713-3699

**MAIL ADDRESS:**
- **STREET 1:** 100 TECHNOLOGY CENTER DRIVE
- **CITY:** STOUGHTON
- **STATE:** MA
- **ZIP:** 02072

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** COLLEGIUM PHARMACEUTICAL INC
- **DATE OF NAME CHANGE:** 20031020

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Freund John Gordon<br><sub>(Last) (First) (Middle)</sub><br>C/O COLLEGIUM PHARMACEUTICAL, INC.<br>100 TECHNOLOGY CENTER DRIVE<br><sub>(Street)</sub><br>STOUGHTON, MA 02072<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2026-05-14 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>COLLEGIUM PHARMACEUTICAL, INC [ COLL ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2026-05-14 |  | A<sup>(1)</sup> |  | 8741 | A | $0 | 79399 | D |  |
| Common Stock | 2026-05-15 |  | M |  | 8700 | A | $16.49 | 88099 | D |  |
| Common Stock | 2026-05-15 |  | S |  | 4127 | D | $34.54 | 83972 | D |  |
| Common Stock |  |  |  |  |  |  |  | 23129 | I | By: John Freund Family Partnership IV, L.P.<sup>(2)</sup> |
| Common Stock |  |  |  |  |  |  |  | 8625 | I | By: Skyline Venture Management V, LLC<sup>(3)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Option (Right to Purchase) | $16.49 | 2026-05-15 |  | M |  |  | 8700 | <sup>(4)</sup> | 2026-06-09 | Common Stock | 8700 | $0 | 0 | D |  |

---

### Footnotes:

(1) Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 14, 2027, or the date of the Issuer's 2027 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock.

(2) The shares are held by the John Freund Family Partnership IV, L.P. ("Freund LP"). The Reporting Person is the trustee and beneficiary of the The John G. Freund Revocable Trust u/a/d 6/26/01 which serves as the general partner of Freund LP. The Reporting Person disclaims beneficial ownership of the shares held by Freund LP except to the extent of his proportionate pecuniary interest therein.

(3) The shares are held by Skyline Venture Management V, LLC. John G. Freund and Yasunori Kaneko are managers of Skyline Venture Management V, LLC. These individuals share voting and investment power over the shares held by Skyline Venture Management V, LLC. The Reporting Person disclaims beneficial ownership of all the shares held by Skyline Venture Management V, LLC except to the extent of his proportionate pecuniary interest therein.

(4) The option is fully vested and exercisable.

**Signature:** /s/ Colleen Tupper as Attorney-in-Fact for John G. Freund, MD  
**Date:** 2026-05-18

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**